Positive impact of hormone replacement therapy on the fibrinolytic system: A long-term randomized controlled study in healthy postmenopausal women

Journal of Thrombosis and Haemostasis

Volumn 1, Issue 9, 2003, Pages 1984-1991

  Madsen, J S ^a   Kristensen, S R ^a   Gram, J ^a,b   Bladbjerg, E M ^b   Henrlksen, F L ^a   Christensen, K ^c   Jespersen, J ^b  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Fibrinolysis; Hormone replacement therapy; Polymorphism

Indexed keywords

DRUG DERIVATIVE; ESTROGEN; NORETHISTERONE; NORETHISTERONE ACETATE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; DRUG EFFECT; FEMALE; FIBRINOLYSIS; GENETIC POLYMORPHISM; GENETICS; HORMONE SUBSTITUTION; HUMAN; MIDDLE AGED; MULTICENTER STUDY; PHYSIOLOGY; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL;

DRUG THERAPY, COMBINATION; ESTROGENS; FEMALE; FIBRINOLYSIS; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; NORETHINDRONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; POSTMENOPAUSE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 2442609956     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1046/j.1538-7836.2003.00362.x     Document Type: Article

References (45)

1. Gensini GF, Micheli S, Prisco D, Abbate R. Menopause and risk of cardiovascular disease. Thromb Res 1996; 84: 1-19.
2. Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health 1998; 19: 55-72.
3. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605-13.
4. Hulley S, Furberg C, Barrett-Connor E, Cauley J, Grady D, Haskell W, Knopp R, Lowery M, Satterfield S, Schrott H, Vittinghoff E, Hunning-hake D. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002; 288: 58-66.
5. Grodstein F, Manson JE, Stampfer MJ. Postmenopausal hormone use and secondary prevention of coronary events in the nurses' health study: a prospective, observational study. Ann Intern Med 2001; 135: 1-8.
6. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative rando mized controlled trial. JAMA 2002; 288: 321-33.
7. van Baal WM, Kooistra T, Stehouwer CD. Cardiovascular disease risk and hormone replacement therapy (HRT): a review based on rando mised, controlled studies in postmenopausal women. Curr Med Chem 2000; 7: 499-517.
8. Gebara OC, Mittleman MA, Sutherland P, Lipinska I, Matheney T, Xu P, Welty FK, Wilson PW, Levy D, Muller JE. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Circulation 1995; 91: 1952-8.
9. Lowe GD, Upton MN, Rumley A, McConnachie A, O'Reilly DS, Watt GC. Different effects of oral and transdermal hormone replacementtherapies on factor IX, APC resistance, t-PA, PAI and C-reactive protein: a cross-sectional population survey. Thromb Haemost 2001; 86: 550-6.
10. Smith FB, Lee AJ, Hau CM, Rumley A, Lowe GD, Fowkes FG. Plasma fibrinogen, haemostatic factors and prediction of peripheral arterial disease in the Edinburgh Artery Study. Blood Coagul Fibrinolysis 2000; 11: 43-50.
11. Thogersen AM, Jansson JH, Boman K, Nilsson TK, Weinehall L, Huhtasaari F, Hallmans G. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998; 98: 2241-7.
12. Gram J, Bladbjerg EM, Moller L, Sjol A, Jespersen J. Tissue-type plasminogen activator and C-reactive protein in acute coronary heart disease. A nested case-control study. J Intern Med 2000; 247: 205-12.
13. Folsom AR, Aleksic N, Park E, Salomaa V, Juneja H, Wu KK. Prospective study of fibrinolytic factors and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vase Biol 2001; 21: 611-7.
14. van Baal WM, Emeis JJ, van der Mooren MJ, Kessel H, Kenemans P, Stehouwer CD. Impaired procoagulant-anticoagulant balance during hormone replacement therapy? A randomised, placebo-controlled 12-week study. Thromb Haemost 2000; 83: 29-34.
15. Teede HJ, McGrath BP, Smolich JJ, Malan E, Kotsopoulos D, Liang YL, Peverill RE. Postmenopausal hormone replacement therapy increases coagulation activity and fibrinolysis. Arterioscler Thromb Vase Biol 2000; 20: 1404-9.
16. Gottsater A, Rendell M, Hulthen UL, Berntorp E, Mattiasson I. Hor mone replacement therapy in healthy postmenopausal women: a ran domized, placebo-controlled study of effects on coagulation and fibrinolytic factors. J Intern Med 2001; 249: 237-46.
17. Davidson MH, Maki KC, Marx P, Maki AC, Cyrowski MS, Nanavati N, Arce JC. Effects of continuous estrogen and estrogen-progestin repla cement regimens on cardiovascular risk markers in postmenopausal women. Arch Intern Med 2000; 160: 3315-25.
18. Sporrong T, Mattsson LA, Samsioe G, Stigendal L, Hellgren M. Haemostatic changes during continuous oestradiol-progestogen treatment of postmenopausal women. Br J Obstet Gynaecol 1990; 97: 939-44.
19. Andersen LF, Gram J, Skouby SO, Jespersen J. Effects of hormone replacement therapy on hemostatic cardiovascular risk factors. Am J Obstet Gynecol 1999; 180: 283-9.
20. Mosekilde L, Hermann AP, Beck-Nielsen H, Charles P, Nielsen SP, Sorensen OH. The Danish Osteoporosis Prevention Study (DOPS): project design and inclusion of 2000 normal perimenopausal women. Maturitas 1999; 31: 207-19.
21. Mansfield MW, Stickland MH, Grant PJ. Plasminogen activator inhi bitor-1 (PAI-1) promoter polymorphism and coronary artery disease in non-insulin-dependent diabetes. Thromb Haemost 1995; 74: 1032-4-.
22. Ludwig M, Wohn KD, Schleuning WD, Olek K. Allelic dimorphism in the human tissue-type plasminogen activator (TPA) gene as a result of an Alu insertion/deletion event. Hum Genet 1992; 88: 388-92.
23. Lobo RA, Bush T, Carr BR, Pickar JH. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. Fertil Steril 2001; 76: 13-24.
24. Chen FP, Lee N, Soong YK, Huang KE. Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on cardiovascular risk factors. Menopause 2001; 8: 347-52.
25. Koh KK, Mincemoyer R, Bui MN, Csako G, Pucino F, Guetta V, Waclawiw M, Cannon RO III. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med 1997; 336: 683-90.
26. Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arterioscler Thromb Vase Biol 1997; 17: 3071-8.
27. Gilabert J, Estelles A, Cano A, Espana F, Barrachina R, Grancha S, Aznar J, Tortajada M. The effect of estrogen replacement therapy with or without progestogen on the fibrinolytic system and coagulation inhibitors in postmenopausal status. Am J Obstet Gynecol 1995; 173: 1849-54.
28. Koh KK, Home MK III, Csako G, Waclawiw MA, Cannon RO III. Relation of fibrinolytic potentiation by estrogen to coagulation pathway activation in postmenopausal women. Am J Cardiol 1999; 83: 466-9.
29. Boschetti C, Cortellaro M, Nencioni T, Bertelli V, Della VA, Zanussi C. Short- and long-term effects of hormone replacement on blood coagu lation factors in postmenopausal women. Thromb Res 1991; 62: 1-8.
30. Gebara OC, Mittleman MA, Walsh BW, Lipinska I, Welty FK, Bellotti G, Muller JE, Sacks FK, Tofler GH. Fibrinolytic potential is signifi cantly increased by oestrogen treatment in postmenopausal women with mild dyslipidaemia. Heart 1998; 80: 235-9.
31. Hahn L, Mattsson LA, Andersson B, Tengborn L. The effects of oestrogen replacement therapy on haemostatic variables in postmeno pausal women with non-insulin-dependent diabetes mellitus. Blood Coagul Fibrinolysis 1999; 10: 81-6.
32. Cushman M, Meilahn EN, Psaty BM, Kuller LH, Dobs AS, Tracy RP. Hormone replacement therapy, inflammation, and hemostasis in elderly women. Arterioscler Thromb Vase Biol 1999; 19: 893-9.
33. Estelles A, Cano A, Falco C, Espana F, Gilabert J, Grancha S, Aznar J. Lipoprotein (a) levels and isoforms and fibrinolytic activity in post-menopause: influence of hormone replacement therapy. Thromb Haemost 1999; 81: 104-10.
34. Henry M, Chomiki N, Scarabin PY, Alessi MC, Peiretti F, Arveiler D, Ferrieres J, Evans A, Amouyel P, Poirier O, Cambien F, Juhan-Vague I. Five frequent polymorphisms of the PAI-1 gene: lack of association between genotypes, PAI activity, and triglyceride levels in a healthy population. Arterioscler Thromb Vase Biol 1997; 17: 851-8.
35. Stegnar M, Uhrin P, Peternel P, Mavri A, Salobir-Pajnic B, Stare J, Binder BR. The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thromboembolism. Thromb Haemost 1998; 79: 975-9.
36. Ye S, Green FR, Scarabin PY, Nicaud V, Bara L, Dawson SJ, Humphries SE, Evans A, Luc G, Cambou JP. The 4G/5G genetic polymorphism inthe promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Thromb Haemost 1995; 74: 837-41.
37. Brown NJ, Abbas A, Byrne D, Schoenhard JA, Vaughan DE. Compara tive effects of estrogen and angiotensin-converting enzyme inhibition on plasminogen activator inhibitor-1 in healthy postmenopausal women. Circulation 2002; 105: 304-9.
38. Grancha S, Estelles A, Tormo G, Falco C, Gilabert J, Espana F, Cano A, Segui R, Aznar J. Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and increased PAI-1 circulating levels in postmeno pausal women with coronary artery disease. Thromb Haemost 1999; 81: 516-21.
39. Jem C, Ladenvall P, Wall U, Jem S. Gene polymorphism of t-PA is associated with forearm vascular release rate of t-PA. Arterioscler Thromb Vase Biol 1999; 19: 454-9.
40. van der Bom JG, de Knijff P, Haverkate F, Bots ML, Meijer P, de Jong PT, Hofman A, Kluft C, Grobbee DE. Tissue plasminogen activator and risk of myocardial infarction. The Rotterdam Study. Circulation 1997; 95: 2623-7.
41. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Miletich JP. Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men. Circulation 1997; 95: 59-62.
42. Steeds R, Adams M, Smith P, Channer K, Samani NJ. Distribution of tissue plasminogen activator insertion/deletion polymorphism in myo cardial infarction and control subjects. Thromb Haemost 1998; 79: 980-4.
43. Madsen JS, Kristensen SR, Klitgaard NA, Bladbjerg EM, Abrahamsen B, Stilgren L, Jespersen J. Effect of long-term hormone replacement therapy on plasma homocysteine in postmenopausal women: a rando mized controlled study. Am J Obstet Gynecol 2002; 187: 33-9.
44. Bladbjerg EM, Skouby SO, Andersen LF, Jespersen J. Effects of different progestin regimens in hormone replacement therapy on blood coagulation factor VII and tissue factor pathway inhibitor. Hum Reprod 2002; 17: 3235-41.
45. Writing Group for the 3rd European Conference on Sex Steroids and Cardiovascular diseases. The European Consensus Development Con ference 2002: Sex Steroids and Cardiovascular Diseases. On the route to combined evidence from OC and HRT/ERT Maturitas 2003; 44: 69-82.